Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?
FACULTY
HARA OYEDEJI, DNP, PMHNP-BC
Founder & Lead Clinician
Fortitude Wellness Group
Owings Mills, Maryland
BRITTANY B. ALBRIGHT, MD, MPH
Founder & CEO
Sweetgrass Psychiatry
Mount Pleasant, South Carolina
INTENDED LEARNERS
This educational activity is intended for nurse practitioners, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.
LEARNING OBJECTIVES
After participating in this activity, learners should be able to:
-
Identify the limitations of monoaminergic antidepressants, including delayed onset, incomplete efficacy, and residual symptoms, and the need for novel therapeutic mechanisms
-
Evaluate the current understanding of the role of the glutamatergic system in the pathophysiology of MDD and its implications for treatment targets
-
Assess the mechanisms of action and most recent clinical data associated with current and emerging glutamatergic treatments for MDD, and evidence that demonstrates their effects on the pathophysiology of MDD and TRD
-
Apply evidence-based strategies to optimize treatment outcomes and address unmet needs in patients with TRD
ACTIVITY OVERVIEW
This on-demand webcast is available with synchronized slides and video/audio.
To be eligible for documentation of credit for each session attended, learners must participate in the activity, and complete the activity evaluation. Participants who complete the evaluation online within active dates will receive documentation of credit. Your certificate may not load if you are accessing it from a smartphone, or if your browser settings do not allow a new tab/window to open.
Once a certificate has been claimed, physicians and pharmacists may elect for credits to be submitted on their behalf to their boards via additional fields that will appear within the Claim Certificate page. Credits must be submitted through this process to be reported to the American Board of Surgery and the National Association of Boards of Pharmacy.
Release Date: May 4, 2026
Expiration Date: May 4, 2027
Estimated Time to Complete: 1.00 hour
HARDWARE/SOFTWARE REQUIREMENTS
The activity is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications.
CONTINUING EDUCATION
In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.
PHYSICIANS
HMP Education designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES
This continuing nursing education activity awards 1.00 contact hours.
Provider approved by the California Board of Registered Nursing, Provider #18006, for 1.00 contact hours.
NURSE PRACTITIONERS
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters, or moderators and do not necessarily reflect the opinions of HMP Education.
DISCLAIMERS
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own healthcare provider.
The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to and mitigating all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
-
Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
-
Any investigational, off-label, or non-FDA approved content or discussion
HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, including any AI-supported elements, mitigate identified financial relationships (conflicts of interest), and ensure:
-
All recommendations involving clinical medicine are based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
-
All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
-
Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
All relevant financial relationships have been mitigated.
FACULTY
The faculty have reported the following:
Hara Oyedeji, DNP, PMHNP-BC, MSEd: Advisory Board– AbbVie, Alkermes, Bristol Myers Squibb, Intra-Cellular Therapies, Johnson & Johnson, Karuna, Neurocrine Biosciences, Otsuka, Sage Therapeutics, Sunovion, Teva Pharmaceuticals; Consultant– AbbVie, Alkermes, Biogen, Bristol Myers Squibb, Intra-Cellular Therapies, Johnson & Johnson, Karuna, Neurocrine Biosciences, Otsuka, Sage Therapeutics, Sunovion, Teva Pharmaceuticals; Speaker's Bureau– Alkermes, Axsome Therapeutics, Bristol Myers Squibb, Johnson & Johnson, Luye Pharma Group, Neurocrine Biosciences, Teva Pharmaceuticals
Brittany Albright, MD, MPH: Advisory Board – AbbVie, Bristol Myers Squibb, Definium Therapeutics, Eli Lilly, Johnson & Johnson, Neurocrine Biosciences; Consultant – AbbVie, Johnson & Johnson, Osmind EHR, Precision Genetics; Speaker's Bureau – AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Johnson & Johnson
CLINICAL REVIEWER
Craig Chepke, MD, DFAPA
Adjunct Associate Professor of Psychiatry
Atrium Health Medical Director Excel Psychiatric Associates
Huntersville, North Carolina
Craig Chepke, MD, DFAPA: Advisory Board—AbbVie, Acadia, Alkermes, Axsome, Biogen, Bristol Myers Squibb, Corium, Idorsia, Intra-Cellular, Johnson & Johnson, Lundbeck, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Teva; Advisory Board (Spouse)—Otsuka; Consultant—AbbVie, Acadia, Alkermes, Axsome, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intra-Cellular, Johnson & Johnson, Lundbeck, MedinCell, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Supernus, Teva; Grant Research/Support—Acadia, Axsome, Harmony, Neurocrine, Teva; Speakers Bureau—AbbVie, Acadia, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intra-Cellular, Johnson & Johnson, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sumitomo, Teva
PLANNING COMMITTEE
Planning for this activity was conducted by faculty advisors. To further support the development of the content, additional information regarding professional roles, responsibilities, and teamwork was gathered through survey input from our target audience and/or a comprehensive literature review.
Andrew D. Penn, MS, PMHNP-BC
University of California, San Francisco, School of Nursing San Francisco, Calirfornia
Atrium Health Medical Director Excel Psychiatric Associates
Huntersville, North Carolina
Andrew Penn, MS, PMHNP-BC: Advisory Board— Alkermes PLC, NACCME, Osmind, Compass Pathways Otsuka, Tactogen; Consultant— 1440 Foundation, Alkermes PLC, Board of Psychedelic Medicine and Therapies California Institute of Integral Studies, Luciem, Definium Theraputics, NACCME, Otsuka. Grant/Research Support—Filament, MAPS, Usona; Employee: Kaiser Permanente (ended 2019), UCSF, Salma Health
The planning committee includes Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, FAAN; Andrew Penn, MS, PMHNP-BC; and, at HMP Education Jordan Bacon, Meaghan Benci, Kristin Ciszeski, Samantha Joy, Josh Raitt, Randy Robbin, and Andrea Zimmerman, EdD, CHCP. No HMP Education staff have disclosed any relevant f inancial relationship with an ineligible company (commercial interest). Planning Committee disclosures are included with faculty disclosures.
ADA STATEMENT
HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. Any participant in this educational activity who needs accommodation(s) may submit a request to the support team.
PRIVACY POLICY
HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
COMMERCIAL SUPPORT
Supported by an educational grant from Johnson & Johnson.
CONTACT US
For immediate assistance, please explore our HMP Education Help Center or chat with our Virtual CE Assistant, which can answer most common questions related to claiming credits and the HMP Education website. If you have a question or grievance that cannot be answered by our Virtual CE assistant and Help Center, please contact the support team. Our accreditation and compliance team will respond to your inquiry within one business day.
Copyright © 2026 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.